What is AMRX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 6.25B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for AMRX?

P/E (TTM) is 39.72 and 52-week range is $9.56 to $21.18 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s AMRX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for AMRX?

The company profile lists revenue (TTM) near $3.03B, net income (TTM) near $153M, EPS (TTM) near $0.48 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Amneal Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Bridgewater, New Jersey, US, 319.3M shares outstanding, ISIN US03168L1052 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Amneal Pharmaceuticals Inc

$AMRX

Health Care · Pharmaceuticals

IR Run Scenarios

$19.57

-2.30%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. The company is headquartered in Bridgewater, New Jersey and currently employs 8,500 full-time employees. The company went IPO on 2009-11-18. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.

Employees

8,500

Website

amneal.com/

IPO

2009-11-18

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)